InvestorsHub Logo
Followers 34
Posts 14191
Boards Moderated 1
Alias Born 03/27/2014

Re: BubbaInSC post# 17568

Thursday, 07/20/2017 6:42:39 AM

Thursday, July 20, 2017 6:42:39 AM

Post# of 37493
What OMHE Drug Is Currently in Human Trials? NONE

OMHE hasn't even specified what they're researching.
Why would one want to trade on this company when they won't specify what it is that they're supposedly "researching"? That's just baiting at it's best....rflmao.


They also need to raise another $5 Million - all for lining up an insider's pocket


0 in research pipeline
0 in human trials
0 that have passed FDA.

How long does it take for a drug to be approved by the FDA?
http://www.medicinenet.com/script/main/art.asp?articlekey=9877

In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to your medicine cabinet. That is, if it makes it. Only 5 in 5,000 drugs that enter preclinical testing progress to human testing. One of these 5 drugs that are tested in people is approved.



True research merely drains “resources” to pay for the researcher's salaries. For a startup that has 0 approved drugs on the market, 0 medications in trials, and a company that hasn't even specified what they're researching – I would say it has SCAM written all over it.

What are the names of the medications that Dr. Uryash has actually researched, developed, tested, passed FDA, and made to market?
https://finance.yahoo.com/news/omni-health-inc-announces-formation-110000089.html

Dr. Arkady Uryash, MD, PhD.

Dr. Uryash is the Director of Biomedical Research for the internship program of Mount Sinai Medical Center and Associate Professor of Cardiology and Vascular Biology for Mount Sinai Center in Miami. As an experienced Director of Research and Development, Dr. Uryash is knowledgeable in U.S. Food and Drug Administration (FDA) regulation, research and development, and clinical trials. Dr. Uryash has previously served as CEO of a biotech company and is experienced in the management of biotech company operations, interdisciplinary team recruitment, and intellectual property. He has published numerous articles in peer-review journals and is a recipient of several academic awards and honors.





Like I've already said before, Andrey owns Le Scam. OMHE will pay Andrey lots of $$$$ for it; which is consistent w/ MCIG's MO of paying insiders at any and all costs to the detriment of shareholders and the net bottom line.

After OMHE adds cbd to Le Scam, they will have Le Scam II

Everyone knows that anything "anti-aging" is a SCAM.


http://marijuanastocks.com/omni-health-inc-omhe-adds-dr-lawrence-e-samuels-to-scientific-advisory-board/

Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke’s Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors’ offices and medical facilities.

Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He’s a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.






FL MJ Cultivation Farms/Nurseries

The likelihood of OMHE succeeding in actual cultivation, production, or selling recreational or medical marijuana is slim to none. I'm not talking about "research"
5/2/17
http://www.otcmarkets.com/stock/FFRMF/news?id=157730

As previously announced, Future Farm signed a LOI to acquire a 10-acre operating greenhouse in Florida, which is in a designated zone to legally cultivate, process and dispense cannabis. The greenhouse fits Florida's stringent criteria for agricultural farmers looking to manufacture cannabis which, under the current law, applicants had to have been in business in Florida for at least 30 years and grow a minimum of 400,000 plants at the time they applied.






If OMHE really does intend to "buy" - it's going to cost tens of millions of dollars to buy an active nursery for the purpose of cultivating marijuana. You don't think that a potential nursery seller is going to know that? RFLMAO

And, from a business perspective, a nursery owner would probably just cultivate marijuana themselves - AND GENERATE $100's of Millions of revenues over the lifetime of the mj nursery.

Here we come - dilution, raising cash via additional stock offerings, or more debt - HERE WE COME!!

Buy, buy, buy. We have to support paying insiders...